Core Viewpoint - Hagens Berman is alerting investors about a pending class action against CoreWeave, Inc. for allegedly misleading the market regarding its AI infrastructure scalability and revenue guidance [1][4] Allegations of Misrepresentation - The lawsuit claims that CoreWeave overstated its capacity to meet customer demand and downplayed operational risks associated with reliance on a single third-party data center supplier [2][7] - Significant delays at the Denton, Texas data center have been revealed, which were reportedly months behind schedule, leading to a market capitalization drop of approximately $14 billion [2][7] Market Reaction - Following the company's lowered guidance, there was a notable stock drop of 16% on November 11, contributing to a significant loss in shareholder value [7] Investigation Details - Reed Kathrein, the partner leading the investigation, emphasized the gap between the company's growth assurances and the reality of construction delays at its primary data center sites [3][4] - The complaint alleges that CoreWeave's ability to recognize revenue from its multibillion-dollar backlog was contingent on infrastructure that was not on track for timely completion [7] Next Steps for Investors - Investors who purchased CoreWeave shares during the Class Period (March 28, 2025 – December 15, 2025) and suffered losses are encouraged to submit their claims [5][6]

Core Insights - Corporate accountability has primarily been represented through presentations, including ESG decks and sustainability summaries, along with carefully worded disclosures [1] Group 1 - The focus on corporate accountability has shifted from mere presentations to more substantive measures [1]

Core Viewpoint - A securities class action lawsuit has been filed against James Hardie Industries plc, alleging that the company and its executives made materially false and misleading statements regarding the health of its North America Fiber Cement segment, leading to a significant stock drop of over 34% when the truth was revealed [2][5]. Summary by Sections Lawsuit Allegations - The lawsuit claims that James Hardie executives misled investors by asserting that the North America segment was strong and that distributor inventory levels were normal, despite knowing that distributors were aggressively destocking inventory [3][4]. - Management allegedly inflated sales figures by loading inventory rather than reflecting genuine demand, using terms like "robust" and "normal" to describe the market conditions [4]. Timeline and Key Details - Class Period: May 20, 2025 – August 18, 2025 - Lead Plaintiff Deadline: December 23, 2025 - Stock Drop: The stock fell over 34% on August 20, 2025, following the disclosure of a 12% decline in North America sales due to customer destocking [5]. Next Steps for Investors - Investors who purchased James Hardie stock during the class period and experienced substantial losses are encouraged to contact Hagens Berman to discuss legal options and potential appointment as Lead Plaintiff [6].

SAN FRANCISCO--(BUSINESS WIRE)--National shareholder rights law firm Hagens Berman has opened an investigation into ALT5 Sigma Corporation (NASDAQ: ALTS) following a cascade of regulatory and management failures that led to the company's stock cratering nearly 80%. Finally, on November 28, 2025, ALT5 disclosed that its outside auditor resigned the same day the company fired CFO Hugh. By August 29, 2025, just weeks after closing a $1.5 billion offering, ALT5 revealed that "on May 7, 2025, the Intermediate Co ...

Core Viewpoint - A class-action lawsuit has been filed against KBR, Inc. alleging misleading statements to investors prior to the cancellation of a significant military contract, which adversely affected the company's business outlook [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired KBR securities between May 6, 2025, and June 19, 2025 [1][2]. - The legal action claims that KBR executives provided an overly optimistic outlook on the HomeSafe partnership just before its collapse [2][5]. Group 2: Contract Cancellation Impact - The Department of Defense's U.S. Transportation Command (TRANSCOM) canceled its global household goods contract with HomeSafe Alliance LLC, a joint venture led by KBR, leading to a more than 7% drop in KBR's share price [3][5]. - The contract was valued at up to $20 billion over a potential nine-year term [3]. Group 3: Financial Implications - KBR had previously assured investors during its Q1 earnings call on May 6, 2025, that the HomeSafe partnership was "strong" and expected to contribute approximately $400 million in revenue for 2025 [4]. - Following the contract termination, KBR revised its low-end 2025 revenue guidance downward by about $900 million (-9%) due to the removal of the HomeSafe JV revenue contribution [6].

Core Viewpoint - A securities fraud class action has been filed against Fiserv, Inc. following a 47% drop in its share price due to disappointing Q3 2025 financial results and significantly lowered guidance [1][2] Financial Performance - Fiserv's Q3 2025 results were described as "abysmal" with a significant earnings miss and a drastic cut in guidance that analysts found difficult to comprehend [2] - The company revised its 2025 organic revenue guidance to 10%, which was the low end of its previous range, and adjusted its EPS guidance upward to $10.15 on July 23, 2025 [5] - On October 29, 2025, Fiserv reported a sequential decline in adjusted revenue, slashing organic revenue growth expectations to 3.5%-4% and EPS outlook to $8.50-$8.60 [7] Management Changes - Following the poor performance, Fiserv announced the departure of its chief financial officer and a shake-up of its board of directors, including the replacement of the head of the audit committee effective January 1, 2026 [7] Investor Reaction - The market reacted negatively, causing Fiserv's share price to drop over $59 in intraday trading, resulting in a loss of $32 billion in shareholder value in one day [9] Legal Proceedings - The class action lawsuit seeks to represent investors who acquired Fiserv securities between July 23, 2025, and October 29, 2025, focusing on allegations that Fiserv misled investors regarding its financial performance [2][4] - Hagens Berman is investigating claims that Fiserv's assurances about its expected financial performance were misleading and based on unrealistic assumptions [3][6]

Core Insights - Fiserv, Inc. experienced a significant decline in share price, dropping over $59 (-47%) following the release of disappointing Q3 2025 financial results, which analysts described as "abysmal" [1][5][7] Financial Performance - The company reported a sequential decline in Q3 2025 adjusted revenue and reduced organic revenue growth expectations to 3.5%-4% [5] - Fiserv also lowered its earnings per share (EPS) outlook to $8.50-$8.60 [5] Leadership Changes - Following the financial results, Fiserv announced the departure of its chief financial officer and a shake-up in its board of directors, including the replacement of the non-executive chairman and the head of the audit committee, effective January 1, 2026 [5][6] Market Reaction - The market reacted swiftly, resulting in a loss of $32 billion in shareholder value in a single day, with analysts expressing disbelief at the magnitude of the earnings miss and guidance cut [7] Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether Fiserv misled investors regarding its financial performance and growth prospects [2][7]

Core Viewpoint - A jury awarded $20 million to the family of Dr. Alberto A. Casaretto, determining that Johnson & Johnson's talc-based products caused his fatal mesothelioma, highlighting corporate accountability for unsafe consumer products [1][7]. Summary by Sections Lawsuit Details - The lawsuit was initiated by Dr. Casaretto's son, alleging that Johnson & Johnson's talc was contaminated with asbestos and that the company failed to warn consumers about the risks [1][2]. - Dr. Casaretto used the talc-based products for decades, believing them to be "pure" and "safe," while evidence showed the company was aware of the asbestos risk but continued to market the products as safe [2][7]. Legal Commentary - Plaintiff counsel emphasized that the verdict represents justice for families unaware of the dangers in Johnson's Baby Powder and reflects a demand for corporate accountability [4]. - The verdict is seen as a significant step against decades of corporate concealment, with the jury's decision underscoring the need for manufacturers to ensure product safety and transparency [4]. Company Accountability - Internal documents and expert testimony revealed that Johnson & Johnson knew about the asbestos risk in talc and chose inadequate testing protocols, opting not to replace talc with safer alternatives [7]. - The $20 million award is a compensatory damage reflecting the jury's recognition of the long-term health ramifications of the company's products [7]. Background Information - Dr. Casaretto was a physician in Florida who passed away in 2022 from malignant pleural mesothelioma, with evidence linking his illness to the use of Johnson & Johnson's talc products [7]. - Levin Papantonio, the law firm representing the plaintiff, has a history of handling mass torts and has secured over $80 billion in jury verdicts and settlements against major corporations [8].

Core Viewpoint - A securities class action lawsuit has been filed against Snap Inc. and certain senior executives, alleging misleading representations regarding its digital advertising platform and growth prospects, following a significant decline in stock price after Q2 financial results [1][4]. Group 1: Lawsuit Details - The lawsuit claims Snap provided false assurances about the effectiveness of its advertising platform and its revenue-driving potential, while actually facing negative impacts from a major "execution error" related to recent changes in the ad platform [4]. - The alleged misleading information became apparent on August 5, 2025, when Snap reported Q2 2025 results, missing analyst estimates for GAAP EPS and revealing a drastic slowdown in ad revenue growth from 9% in Q1 to just 1% in April [5]. Group 2: Financial Impact - Following the Q2 report, Snap's stock price dropped approximately 17% the next day due to the disclosed issues with its advertising platform and revenue growth [5]. Group 3: Legal Representation - Hagens Berman, a law firm, is investigating the case and encouraging investors who suffered losses to come forward, questioning whether Snap misled investors about the ad platform changes that led to revenue deceleration and share price decline [6].

Core Viewpoint - Coty Inc. experienced a significant drop in share price following the release of its FY 2025 and Q4 financial results, which highlighted ongoing inventory destocking issues and weak revenue performance [1][4]. Company Overview - Coty Inc. is one of the largest beauty companies, with a diverse portfolio that includes fragrance, color cosmetics, and skin and body care products. The company operates through two reporting segments: Prestige and Consumer Beauty, which contributed approximately 65% and 35% of its revenues in 2025, respectively [2]. Financial Performance - In its Q4 report, Coty disclosed substantial year-over-year revenue declines in both its Prestige and Consumer Beauty segments. The company attributed its poor financial results partly to retailers' inventory reduction, a situation it had previously downplayed since the transition to its digital inventory strategy [4]. Investigation Details - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether Coty misled investors regarding its growth prospects and the effectiveness of its digital inventory strategy, specifically the SAP S/4HANA transition [3][5]. The firm is examining claims that Coty may have overloaded retailers with excess inventory to manage its own inventory buildup and meet earnings expectations [5]. Market Reaction - Following the earnings call and the revelation of inventory issues, Coty's share price fell by $1.05, representing a 21% decrease [1].